Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Naphazoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.97 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naphazoline SCHEMBL29389962 | 1.00 | TAAR1 (1.00) | TAAR1MAPK1CYP2D6NISCHADRA2A | |
| Naphazoline SCHEMBL29369882 | 0.98 | TAAR1 (1.00) | TAAR1MAPK1CYP2D6NISCHADRA2A | |
| Naphazoline SCHEMBL34532 | 0.98 | TAAR1 (1.00) | TAAR1MAPK1CYP2D6NISCHADRA2A | |
| Naphazoline SCHEMBL26087856 | 0.97 | TAAR1 (0.97) | TAAR1MAPK1CYP2D6NISCHADRA2A | |
| Naphazoline SCHEMBL12481545 | 0.97 | TAAR1 (0.97) | TAAR1MAPK1CYP2D6NISCHADRA2A | |
| Naphazoline SCHEMBL1649580 | 0.97 | TAAR1 (0.97) | TAAR1MAPK1CYP2D6NISCHADRA2A | |
| Naphazoline SCHEMBL28732221 | 0.90 | TAAR1 (0.84) | TAAR1MAPK1CYP2D6NISCHADRA2A | |
| Naphazoline SCHEMBL7039049 | 0.90 | TAAR1 (0.84) | TAAR1MAPK1CYP2D6NISCHADRA2A | |
| Naphazoline SCHEMBL16241749 | 0.89 | TAAR1 (0.82) | TAAR1MAPK1CYP2D6NISCHADRA2A | |
| Naphazoline SCHEMBL506167 | 0.88 | TAAR1 (0.80) | TAAR1MAPK1CYP2D6NISCHADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4059 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010841-A | Medicinal soothing preparation and preparation method thereof | 广州大光制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-12594251-B2 | Benzalkonium chloride foruse in treating conjunctivitis and/or covid-19 | BAUSCH + LOMB IRELAND LIMITED (IE) | 2026-04-07 | — | — | US | claimed |
| US-12490932-B2 | Ophthalmic drug delivery | EYENOVIA, INC. (US) | 2025-12-09 | — | — | US | claimed |
| US-20250127760-A1 | COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING PRESBYOPIA | SHENYANG XINGQI PHARMACEUTICAL CO., LTD. (CN) | 2025-04-24 | — | — | US | claimed |
| CN-118641658-B | Method for identifying and detecting two chemical drugs and content in nasal medical instrument | 连云港市食品药品检验检测中心 | 2025-03-28 | — | — | CN | claimed |
| CN-116350790-B | Composition and application thereof in preparation of medicine for treating presbyopia | 沈阳兴齐眼药股份有限公司 | 2025-02-07 | — | — | CN | claimed |
| EP-4458356-A1 | COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING PRESBYOPIA | Shenyang Xingqi Pharmaceutical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | claimed |
| CN-118852014-A | Resource utilization method of naphazoline synthetic waste | 湖北华丹医药科技股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-118706980-A | Method for detecting related substances of cromolyn sodium | 山东天顺药业股份有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-118688341-A | Method for detecting related substances of naphazoline hydrochloride | 山东天顺药业股份有限公司 | 2024-09-24 | — | — | CN | claimed |
| US-5188826-A | Used for dry eye application, consists of crosslinked acrylic acid polymer, one or more demulcents and vasoconstrictors; administered to eye in drop or gel form and releases water | INSITE VISION INCORPORATED (US) | 1993-02-23 | — | — | US | claimed |
| WO-1993000932-A1 | METHOD OF REVERSING LOCAL ANESTHESIA AND REAGENT SYSTEM THEREFOR | ABRAHMSOHN GLENN M (US) | 1993-01-21 | — | — | WO | claimed |
| WO-1992000707-A1 | TOPICAL OPHTHALMIC SUSPENSIONS | INSITE VISION INCORPORATED (US) | 1992-01-23 | — | — | WO | claimed |
| EP-0349763-A1 | Compositions for enhancing transdermal penetration | Bristol-Myers Squibb Company (US) | 1990-01-10 | — | — | EP | claimed |
| EP-0317405-A1 | Ophthalmic solution comprising iodine-polyvinylpyrrolidone complex | Plamondon, Marc (CA) | 1989-05-24 | — | — | EP | claimed |
| US-4741899-A | Process for arresting the proliferation of organisms that convert axillary secretions to malodorous materials | BRISTOL-MYERS COMPANY (US) | 1988-05-03 | — | — | US | claimed |
| US-4603131-A | Method and composition for treating and preventing irritation of the mucous membranes of the nose | BERNSTEIN, JOEL E. | 1986-07-29 | — | — | US | claimed |
| US-4505909-A | Method and composition for treating and preventing irritation of the eyes | BERNSTEIN JOEL E (US) | 1985-03-19 | — | — | US | claimed |
| EP-0093373-A1 | Method and composition for treating and preventing irritation of the mucous membranes of the nose | Bernstein, Joel E. (US) | 1983-11-09 | — | — | EP | claimed |
| EP-0048023-A2 | Composition for treating and preventing irritation of the eyes | Bernstein, Joel E., M.D. (US) | 1982-03-24 | — | — | EP | claimed |